NEW YORK, Jan. 19, 2016 /PRNewswire/ -- PierianDx, the leading provider of genomic software and services to enable data-driven personalized medicine, announced that it closed $9.25 million in Series A financing. This financing will enable PierianDx to expand its lead as a pioneer in Next Generation Sequencing (NGS) software and services. PierianDx will use the funding to accelerate product development and expand sales, marketing and operations efforts.
Chardan acted as sole placement agent on the transaction.
PierianDx's genomics software platform, Clinical Genomicist Workstation (CGW), provides the leading data-driven workflow for health systems, academic medical centers, and commercial labs to improve patient outcomes through more precise genomic analysis, interpretation and reporting. CGW offers clinical labs the ability to deliver on the promise of personalized medicine by providing comprehensive clinical insights for somatic cancer as well as constitutional disorders. CGW does this by providing a highly streamlined workflow and an extensive, curated, constantly updated knowledge base.
PierianDx enables health systems, academic medical centers and commercial labs to deliver patient-specific diagnosis and treatments based on an individual's DNA. In use since 2011, and regularly enhanced with new patient, clinical and research data, PierianDx's proprietary Clinical Genomicist Workstation provides clinical labs more streamlined and accurate analysis, interpretation, and reporting needed to accelerate their personalized medicine programs. For more information, please visit www.pieriandx.com or @PierianDx on Twitter.
About Chardan Capital Markets, LLC
Chardan Capital Markets ("Chardan") provides a full suite of Global Investment Banking services designed for micro, small and mid-cap emerging growth companies. Our full range of services includes capital raising, merger and acquisition advisory, strategic advisory, equity research, institutional trading and market making.
Headquartered in New York City, Chardan is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: FINRA, SIPC, NASDAQ and the NYSE Arca, Inc.
To learn more about Chardan Capital Markets, visit: www.chardancm.com
SOURCE Chardan Capital Markets